Amyris — Investor Day (May 2017)
32 slides from Amyris's investor day presentation, May 16, 2017
Slide 1: Biotech Summit 2017 & Investor Day
1 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Copyright © 2017 Amyris, Inc. CONFIDENTIAL Biotech Summit 2017 & Investor Day May 16, 2017 Innovative Science for a Healthier Planet
Slide 2: Forward-Looking Statements
2 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 This presentation and oral statements accompanying this presentation contain forward - looking statements, and any statements other than statements of historical fact could be deemed to be forward - looking statements. These
Slide 3: Amyris Strategy & Update
3 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Copyright © 2017 Amyris, Inc. CONFIDENTIAL Amyris Strategy & Update John Melo Innovative Science for a Healthier Planet Confidential & Proprietary
Slide 4: Our Promise: Making Better Products For A Healthier Planet
4 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Our Promise Making Better Products For A Healthier Planet
Slide 5: Better products for healthier people
5 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 • Better products for healthier people – Our No Compromise® product promise • Sustainably sourced for a healthier planet • Lowest Cost, better performing products for healthier profits for our partners and Amyris Remaking th
Slide 6: Amyris. We are:
6 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Amyris. We are:
Slide 7: We are winning today in high-growth markets
7 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 We are winning today in high - growth markets Health & Wellness Global Shifts Market Volatility Health & Nutrition Personal Care Performance Materials Food consumption Healthcare concerns Aging population Growing population
Slide 8: Our distinctive and advantaged business model
8 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Our distinctive and advantaged business model removes product and market risk while funding development 1 2 3 4 Target Develop Supply Profit split Upfront funding Milestone payments from partner Sale and profit on shipment t
Slide 9: Fundamentals are driving real revenue from products people want
9 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 2014 2015 2016 2017 2018 2019 Collaboration revenue Personal Care Performance Material Health & Nutrition Fundamentals are driving real revenue from products people want GAAP revenue by sector ex. Fuels, $M $29.6 $66.8 $37.8
Slide 10: Our product revenue scorecard – measure us by this
10 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Our product revenue scorecard – measure us by this 2015 2016 2017 2018 Product & Value-Share Revenue (excluding Fuel) Flavors & Fragrances $M $3 $11 $14 $53 Skincare $M $8 $6 $17 $27 Vitamins $M $6 $24 $32 Sweeteners $M $57
Slide 11: Farnesene production enables a wide range of value capture
11 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Farnesene production enables a wide range of value capture Product Amyris Selling Price ($/kg) Potential Revenue at 22kT ($M/year) Jet Fuel $0.70 $15 Vitamin E $3 $66 HP Polymers $7 $154 Fragrances $14 $308 Emollient $20 $4
Slide 12: Brotas investment enables transformational income generation
12 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Brotas 2 investment enables transformational income generation Molecules produced Status Year 1 Production Fragrance 1 In market Fragrance 2 In market Cosmetic Active 1 2017 Launch Fragrance 3 2017 Launch Fragrance 4 2017 L
Slide 13: Amyris has delivered distinctive performance in sector
13 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Amyris has delivered distinctive performance in sector Product revenue, Amyris* and competitors, $M *Excluding Fuels $0 $2 $4 $6 $8 $10 $12 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16 1Q17 Product revenue, $M Amyris Intrexon BioAmber Ter
Slide 14: Market capitalization to product revenue multiple
14 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 0 50 100 150 200 250 300 350 400 450 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16 1Q17 Product revenue multiple Amyris Intrexon BioAmber TerraVia*** Codexis Upside based on Amyris’ product revenue Market capitalization to product revenue
Slide 15: Technology & production cost advantage enables value share model
15 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Our technology & production cost advantage enables value share business model as a competitive advantage 2014 2015 2016 2017 2018 2019 2020 2021 Collaboration Revenue Product Margin Value Share • Ongoing collaborations driv
Slide 16: Products commercialized, or in pipeline, drive targets
16 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Products commercialized, or in pipeline, drive targets 2014 2015 2016 2017 2018 2019 2020 2021 Projected Revenue Revenue in Pipeline Revenue Commercialized Revenue Collaboration 2017 2018 2019 2020 2021 New products 3 3 3 3
Slide 17: The Sustainability Revolution is real and here
17 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 The Sustainability Revolution is real and here Corporate sustainability trends • Climate change & Paris Agreement (COP21) • Evolution of sustainability reporting trending to make companies held accountable • Employees, inve
Slide 18: New global middle-class drives demand for animal proteins & skincare
18 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 New global middle - class drives demand for animal proteins & skincare products 1 – The World Bank, Kharas and Gertz 2010 4 – World Health Organization 2 – United Nations FAOSTAT 5 – nutraingredients.com 3 – Grand View Rese
Slide 19: Leading partners remove product & market risk
19 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Leading partners remove product & market risk Health & Nutrition • Pharma • Nutraceuticals • Food Ingredients Personal Care • Fragrance ingredients • Skincare • Cosmetic Actives Performance Materials • Lubricants • Polymers
Slide 20: Our technology delivers predictable, low-cost time to market
20 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Our technology delivers predictable, low - cost time to market • Timelines and R&D cost depict estimated strain engineering costs to first pilot (300L) and manufacturing runs • Months to manufacturing also includes process
Slide 21: Innovative science, robotics, and data analytics drive rapid product development
21 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Cellular programming Modify cellular DNA to add new functionality to cells Analytics Collect high throughput, rich data to understand how DNA changes impact cell functionality Data Science Represent the cell computationally
Slide 22: We have proven commercial production capability
22 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 We have proven commercial production capability • Brotas 2, a specialty product facility is under construction, targeted on - line 1Q 2019 • This capability is unprecedented in our sector Ground is broken for Brotas II Our
Slide 23: Brotas II plant design
23 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Brotas II plant design
Slide 24: Products commercialized, or in pipeline, drive targets
24 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Products commercialized, or in pipeline, drive targets Sweetener 1 Vitamin E Collaborations Fragrance 4 Lubes Fragrance 1 2014 2015 2016 2017 2018 2019 2020 2021 Product & collaborations revenue, ex. Fuels, $M Sweetener 2 $
Slide 25: Skincare is a massive and growing market
25 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Skincare is a massive and growing market – It’s easy to identify “Sephora recently confirmed that…Biossance's unscented eye cream is a continual best - seller.” – Allure Magazine • Global personal care products total market
Slide 26: Amyris market share is growing in skincare
26 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Amyris market share is growing in skincare In a few short years, Amyris has captured over 20% of the squalane market. Cosmetics ingredients business creates access to 600 brands through our strategic partners, their channel
Slide 27: "Amyris Inside" Cosmetic Brands
27 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 “Amyris Inside” Cosmetic Brands
Slide 28: Vitamins help grow healthy, heavier animals
28 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 0 500 1000 1500 2000 2500 3000 2004 2008 2012 2016 $0.0 $0.2 $0.4 $0.6 $0.8 $1.0 $1.2 $1.4 $1.6 2009 2011 2013 2015 2017 2019 2021 Vitamins help grow healthy, heavier animals very fast – providing protein the world needs an
Slide 29: Sugar reduction market is a step-out opportunity
29 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Sugar reduction market is a step - out opportunity In 2017 sugar - replacement market is $8.7B 9% of $97B sweeteners Amyris technology will disrupt today’s stevia - based sugar replacements We plan to launch our first produ
Slide 30: Today and looking ahead
30 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 Today and looking ahead 1) We have underpinned line - of - sight into Amyris’ growth: • >$900M by 2021 • > 90% w/ existing customers & products already commercialized or near launch 2) We are addressing our balance sheet: •
Slide 31: Our track record
31 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12 • Over 10 products now generate at least $1M in annual sales • 3 brands that are on track for over $10M in sales this year • 1 molecule that will generate over $30M in revenue this year • All existing partners have or are i
Slide 32: 32 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12
32 232/151/55 0/90/132 145/145/149 178/187/30 185/52/75 105/109/17 117/76/12